Kyle Lahucik is an Associate Editor for Endpoints News, a leading source of biotech and pharmaceutical news. With a focus on the biotech industry, Kyle covers a wide range of topics including drug discovery, clinical trials, and industry trends. His work has also been featured in Biotech magazine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kyle Lahucik's articles predominantly cover healthcare and pharmaceutical industry, with a strong focus on biotech, drug development, clinical trials, and biotech IPOs. His coverage heavily features press releases and private sector announcements.
Given his extensive reporting on the healthcare and pharmaceutical industry, Kyle would likely be interested in pitches that offer exclusive insights into new drug developments or clinical trial results. Additionally, he may also be open to receiving information about significant partnerships or acquisitions within the biotech and pharmaceutical sectors.
It seems that Kyle does not have a specific geographic focus but rather covers global developments in the healthcare and pharmaceutical industries. Therefore, pitches should center around events of international significance within these sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kyle Lahucik
SAN ANTONIO — Zealand Pharma, hoping to create the next
SAN ANTONIO — As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...
By: Kyle Lahucik
Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm ...
Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new investors are helping back …
Trace Neuroscience, a startup spun out of Maze Therapeutics' pipeline, broke cover Tuesday morning with $101 million in funding to develop treatments for amyotrophic lateral …
Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, the companies said Tuesday morning. …
After initially promising more than $1 billion in biobucks to its partner Biotheus for a single drug, BioNTech is now buying out all of the …
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, Gubra said people …
Summit Therapeutics and its Chinese partner Akeso have a few competitors now. Merck, the maker of the drug they're trying to beat, is entering the …
Halozyme said Thursday post-market that it wants to buy Evotec for €11 per share in cash, giving the struggling drug discoverer …
(833) 317-6278 
